Are You a GLP-1 Nonresponder?

How GLP-1s can improve patient outcomes in joint replacement surgery

FDA Announces Plans to Restrict Non-Approved GLP-1 Drugs in Compounded Medications

The FDA is announcing its intent to take action against non-FDA-approved GLP-1 drugs, specifically targeting GLP-1 active pharmaceutical ing

Obesity care's next generation will combine GLP-1 drugs with personalized therapies and advanced procedures

The article discusses how GLP-1 drugs like Ozempic, Wegovy, and Zepbound have transformed obesity treatment, but experts predict the future

GLP-1 Prescriptions Rise as U.S. Obesity Rates Show Modest Decline, New Data Indicates

New data from EPIC Research shows that GLP-1 medications like Ozempic and Wegovy are having a population-wide impact on obesity rates. As pr

Study: Stopping GLP-1 Drugs Increases Heart Attack and Stroke Risk

New research published in BMJ Medicine reveals that stopping GLP-1 drugs (originally for diabetes, now popular for weight loss) leads to a r

GLP-1 Prescriptions Surge Sevenfold Among Women With PCOS: What to Know About Off-Label Use

GLP-1 drug prescriptions (like Ozempic, Wegovy, Zepbound, Mounjaro) among women with PCOS have surged over sevenfold since 2021, despite the